Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.37 – $1.43
Volume6,529
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.01M
Price / earnings
—
Price / book
0.27×
Price / sales
40.65×
EV / sales
-103.3×
EV / EBITDA
0.98×
Profitability
Earnings per share
-$3.51
Return on assets
-63.86%
Return on equity
-68.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.17×
Quick ratio
14.17×
Cash ratio
13.79×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACON, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$33.73K
$25.21K
$21.14K
$18.48K
$18.94K
$19.32K
$18.99K
$10.23K
Cost of revenue
$18.94K
$16.91K
$17.39K
$16.69K
$14.56K
$14.18K
$23.48K
$20.56K
Gross profit
$14.8K
$8.3K
$3.75K
$1.79K
$4.39K
$5.14K
-$4.49K
-$10.32K
Selling, general and administrative
$2.4M
$2.61M
$2.68M
$1.73M
$1.53M
$1.47M
$1.29M
$1.54M
Research and development
$371.51K
$297.07K
$315.42K
$263.13K
$302.04K
$270.43K
$198.19K
$251.83K
Total operating expenses
$2.77M
$2.91M
$2.99M
$1.99M
$1.84M
$1.74M
$1.49M
$1.8M
Operating income
-$2.75M
-$2.9M
-$2.99M
-$1.99M
-$1.83M
-$1.74M
-$1.49M
-$1.81M
Interest expense
$0
$0
$0
$0
$0
$0
$0
-$271
Income before taxes
-$2.62M
-$2.75M
-$2.85M
-$1.89M
-$1.71M
-$1.6M
-$2.04M
-$1.99M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.62M
-$2.75M
-$2.85M
-$1.89M
-$1.71M
-$1.6M
-$2.04M
-$1.99M
Net income attributable to common shareholders
-$2.62M
-$2.75M
-$2.85M
-$1.89M
-$1.71M
-$1.6M
-$2.04M
-$2.04M
EBITDA
-$2.69M
-$2.84M
-$2.93M
-$1.93M
-$1.77M
-$1.68M
-$1.44M
-$1.75M
Basic earnings per share
-$0.94
-$1.12
-$1.34
-$2.54
-$2.93
-$2.75
-$9.32
—
Diluted earnings per share
-$0.94
-$1.12
-$1.34
-$2.54
-$2.93
-$2.75
-$9.32
—
Recent news
Company coverage with links to the original publishers.
Ardent Health, Inc. (ARDT) reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.24, with revenues of $1.62 billion slightly exceeding expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends. The stock has outperformed the S&P 500 by 22% year-to-date, but future performance will depend on management guidance and earnings estimate revisions.
Aclarion reported 85% year-over-year scan volume growth in Q3 2026 and 117% growth for the nine-month period. The company expanded its CLARITY clinical trial to eleven sites with updated enrollment criteria and published peer-reviewed data in the European Spine Journal supporting its Nociscan technology as an alternative to provocative discography. With $14.2 million in cash, Aclarion has runway into the second half of 2027 to fully fund the 300-patient trial.
Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.
Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform and generate real-world evidence. The partnership will evaluate how Nociscan's chemical biomarker measurements work alongside SPECT-CT imaging to improve diagnostic precision for chronic low back pain treatment decisions.
Aclarion's Nociscan MRS technology was used in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The research found that elevated propionic acid levels in lumbar discs can identify a subgroup of Modic type 1 patients with distinct immune activation, suggesting potential applications beyond surgical decision support for personalized spine care and immune-modulating therapies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.